Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Axsome Thera
(NQ:
AXSM
)
69.71
+0.90 (+1.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Axsome Thera
< Previous
1
2
3
4
Next >
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 12, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
April 10, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
April 01, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
March 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
March 25, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
March 19, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 20, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
5 medical stocks growing earnings by triple digits
February 06, 2024
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning
Via
MarketBeat
Topics
Economy
Exposures
Economy
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
January 23, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
January 04, 2024
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
December 11, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
December 07, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
November 27, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
AXSM FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
November 25, 2023
WHY: NEW YORK, NY - (NewMediaWire) - November 25, 2023 - Rosen Law Firm, a global investor rights law firm, reminds investors of the common stock of Axsome Therapeutics, Inc. (“Axsome”) (NASDAQ: AXSM)...
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
November 24, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
November 22, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
November 21, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
November 18, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM
November 17, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Rosen Law Firm Announces the Reopening of the Lead Plaintiff Appointment Process in a Class Action Against Axsome Therapeutics, Inc. and Certain Officers – AXSM
November 16, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023
November 02, 2023
Axsome’s headquarters to be lit in teal as part of the Alzheimer’s Foundation of America awareness campaign
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Axsome Therapeutics to Present at Upcoming Investor Conferences
October 31, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.